Kazia Therapeutics Ltd logo

Kazia Therapeutics Ltd

ASX:KZA (Australia)  
(Delisted) A$ 0.08 (0%) Nov 15
At Loss
P/B:
0.63
Market Cap:
A$ 18.91M ($ 12.40M)
Enterprise V:
A$ 15.46M ($ 10.14M)
Volume:
-
Avg Vol (2M):
-

Business Description

Description
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 2.92
Equity-to-Asset 0.43
Debt-to-Equity 0.15
Debt-to-EBITDA -0.08
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 50.07
9-Day RSI 47.12
14-Day RSI 43.95
6-1 Month Momentum % -48.72
12-1 Month Momentum % 1.01

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.42
Quick Ratio 1.42
Cash Ratio 0.69

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -32.2
Shareholder Yield % -139.31

Profitability Rank

Name Current Vs Industry Vs History
ROE % -143.85
ROA % -65.79
ROIC % -94.57
ROCE % -98.95

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 0.63
EV-to-EBIT -0.22
EV-to-EBITDA -0.24
EV-to-Forward-EBITDA -1.19
EV-to-Forward-Revenue 2.03
EV-to-FCF -0.35
Earnings Yield (Greenblatt) % -454.55
FCF Yield % -172.89

Financials (Next Earnings Date:2024-08-29 Est.)

ASX:KZA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Kazia Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.112
Beta 0
Volatility % 100.41
14-Day RSI 43.95
14-Day ATR (A$) 0.010469
20-Day SMA (A$) 0.08025
12-1 Month Momentum % 1.01
52-Week Range (A$) 0.051 - 0.24
Shares Outstanding (Mil) 236.35

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Kazia Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Kazia Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Kazia Therapeutics Ltd Frequently Asked Questions

What is Kazia Therapeutics Ltd(ASX:KZA)'s stock price today?
The current price of ASX:KZA is A$0.08. The 52 week high of ASX:KZA is A$0.24 and 52 week low is A$0.05.
When is next earnings date of Kazia Therapeutics Ltd(ASX:KZA)?
The next earnings date of Kazia Therapeutics Ltd(ASX:KZA) is 2024-08-29 Est..
Does Kazia Therapeutics Ltd(ASX:KZA) pay dividends? If so, how much?
Kazia Therapeutics Ltd(ASX:KZA) does not pay dividend.

Press Release

Subject Date
No Press Release